Year: 2026

ROCKVILLE, Md. and SUZHOU, China, April 21, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that six abstracts from clinical studies of three key drug candidates have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in person at McCormick Place in Chicago, IL, and online, May 29 – June 2, 2026. With three abstracts selected for rapid oral presentations and three abstracts selected for poster presentations, these data highlight the global innovation and clinical value of Ascentage Pharma’s portfolio, inclusive...

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) — Figure Technology Solutions (Nasdaq: FIGR; OPEN: FGRS), the leading blockchain-native capital marketplace for the origination, funding, sale, and trading of tokenized assets, today announced that it plans to report its First Quarter 2026 results on Monday, May 11, 2026, after market close. The company will host a conference call to discuss the results, outlook, and related matters the following morning, Tuesday, May 12, 2026, at 8:30 a.m. Eastern Time. A live webcast of the conference call and supporting materials will be available at http://investors.figure.com. For those unable to listen to the live broadcast, a replay will be available at the same website after the event. About Figure Figure Technology Solutions, Inc. (Nasdaq: FIGR; OPEN: FGRS) is a blockchain-native capital marketplace...

Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple sclerosis (RMS) Both studies showed positive trends in reducing disability progression with fenebrutinib compared to teriflunomide Fenebrutinib could become a first-in-class BTK inhibitor and the first and only high-efficacy oral for both RMS and primary progressive multiple sclerosis (PPMS) The totality of RMS and PPMS data for fenebrutinib will be submitted to regulatory authoritiesBasel, 22 April 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the positive Phase III FENhance 1 and 2 studies, which met their primary endpoint. The studies showed that fenebrutinib, an investigational non-covalent Bruton’s tyrosine...

Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS Data underscore potential for miv-cel to become the first and only approved treatment for SPS, fundamentally changing the treatment paradigm for patients and caregivers Company to host conference call on Wednesday, April 22, 2026, at 7:00 am ET EMERYVILLE, Calif., April 21, 2026 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced positive primary analysis results from its registrational trial, KYSA-8, of miv-cel (mivocabtagene autoleucel, KYV-101) in stiff person syndrome (SPS). The data...

CALGARY, Alberta, April 21, 2026 (GLOBE NEWSWIRE) — Enerflex Ltd. (TSX: EFX) (NYSE: EFXT) (“Enerflex” or the “Company”) plans to release its financial results and operating highlights for the three months ended March 31, 2026, on Thursday, May 7, 2026 prior to market open. Results will be communicated by news release and will be available on the Company’s website at www.enerflex.com and under the electronic profile of the Company on SEDAR+ and EDGAR at www.sedarplus.ca and www.sec.gov/edgar, respectively. Investors, analysts, members of the media, and other interested parties, are invited to participate in a conference call and audio webcast on Thursday, May 7, 2026 at 8:00 a.m. (MT), where members of senior management will discuss the Company’s results. A question-and-answer period will follow. To participate, register...

TORONTO, April 21, 2026 (GLOBE NEWSWIRE) — Emerita Resources Corp. (“Emerita” or the “Company”) (TSXV: EMO) (OTCQX: EMOTF) (FSE: LLJA) has become aware of a press release dated April 21, 2026 issued by Denarius Metals Corp. (“Denarius”) pursuant to which Denarius has indicated its intention to make an increased offer to acquire all of the issued and outstanding common shares of Emerita (the “Shares”). Please see the Company’s press release dated April 13, 2026 for further details regarding the initial offer received from Denarius (the “Initial Offer”). Emerita has not received an additional written offer from Denarius following the receipt of the Initial Offer. The Board of Directors of Emerita (the “Board”), in consultation with its advisors, will determine the course of action that is in the best interests of Emerita and its shareholders....

PORTLAND, Tenn., April 21, 2026 (GLOBE NEWSWIRE) — Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a global leader in electrical infrastructure solutions for the energy transition market, announced today its participation in the following upcoming investor events: May 7, 2026: JP Morgan Virtual Fireside Chat Shoals’ CEO, Brandon Moss, and CFO, Dominic Bardos, will participate in a fireside chat with covering analyst Mark Strouse. Interested investors should contact their JP Morgan sales representative. May 13, 2026: Johnson Rice Virtual Fireside Chat Shoals’ VP of Finance & Investor Relations, Matt Tractenberg, and SVP of Sales, Karen Bazela, will participate in a fireside chat with covering analyst Marty Malloy. Interested investors should contact their Johnson Rice sales representative. May 27,...

Total Revenue growth of 13% year-on-year Adjusted EBITDAR Margin of 25% Operating Margin of 11% Liquidity to LTM Revenue ratio at 23%MEXICO CITY, April 21, 2026 (GLOBE NEWSWIRE) — Grupo Aeroméxico S.A.B. de C.V. (NYSE: AERO & BMV: AERO, “Aeroméxico” or the “Company”) today reported unaudited consolidated financial results for the three months ended March 31, 2026 (“1Q26”). These results are based on information available to us as of the date of this earnings release and are not a comprehensive statement of our financial results for the period presented. The Company has used the U.S. dollar, its functional currency, as the presentation currency for its consolidated financial statements. All figures are expressed in millions of U.S. dollars unless otherwise indicated. Andrés Conesa, Chief Executive Officer stated: “Aeroméxico...

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clinical data from two Phase 1/2 trials of daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC). Data from the daraxonrasib combination cohort will be presented in a late-breaking mini-symposium, and data from the monotherapy cohort will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting on April 21, 2026. Findings from both trials support daraxonrasib’s continued evaluation in the first line setting, demonstrating manageable safety and tolerability profiles...